Augusta University

augusta.edu

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

178

Active

24

Phase 3

9

Total enrollment

65,901

Pipeline matrix

Showing 8 of 8 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Olanzapine3
Candesartan1
Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone1
Resveratrol1
Antifungal treatment1
NMD; 0.4mg sub-lingual nitroglycerin spray1
Genetic Testing for hematological malignancies1
Bosentan1

Next readouts

  • 2025-12
  • 2025-12
  • 2026-12
  • 2027-01-01
  • 2027-05-01
  • 2027-10
  • 2027-11-01
  • 2029-02

Top conditions

  • Cardiovascular Diseases10
  • Hypertension10
  • Obesity10
  • Constipation9
  • Fecal Incontinence5
  • Blood Pressure5
  • Heart Diseases5
  • Cystic Fibrosis4

Frequently asked questions about Augusta University

How many clinical trials does Augusta University have on ClinicalTrials.gov?
Augusta University is listed as the lead sponsor on 178 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
How many of Augusta University's trials are in Phase 3?
9 of Augusta University's trials are in Phase 3, spread across 8 active drug programs.
What therapeutic areas does Augusta University focus on?
Augusta University's most-studied conditions on ClinicalTrials.gov are Cardiovascular Diseases, Hypertension, Obesity, Constipation, Fecal Incontinence.
When are Augusta University's next clinical trial readouts?
Augusta University has 8 upcoming primary-completion readouts tracked here; the soonest is “Adiposity and Endothelin Receptor Function”, expected around 2025-12.